Item 1.01 Entry into a Material Definitive Agreement
On September 18, 2009, BioCryst Pharmaceuticals, Inc. (the "Company") entered into a contract modification with the U.S. Department of Health & Human Services (HHS) to advance the development of intravenous (i.v.) peramivir. The modification increases the award under the original contract by $77.2 million for a total of $179.9 million and extends the term of the contract by 12 months for a total term of five years.
Item 7.01 Regulation FD Disclosure
On September 21, 2009, the Company issued a news release with respect to the modification. The news release is furnished as Exhibit 99.1 hereto and is incorporated by reference.
The information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Item 9.01. Financial Statements and Exhibits.

(d) Exhibits Exhibit No. Description 99.1 Press release dated September 21, 2009 entitled "BioCryst Awarded Additional $77.2 million by the U.S. Department of Health & Human Services to Develop Peramivir for Influenza."

---